Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Cell Therapeutics (CTIC) -- Ignore unavailable to you. Want to Upgrade?

To: former_pgs who wrote (456)	2/24/2005 11:45:03 AM
From: quidditch	Read Replies (2) \| Respond to of 946

f_pgs, confused: As to (2): "I find this to be the relatively unlikely scenario." I thought surely you were going to say "likely". Why is there, necessarily, an inconsistency between the theory advanced by CTIC (tumor takes up and retains xyotax) and Miljenko's theory that the xyotax in the blood is being excreted? As a localized site of activity, wouldn't one think that the tumor is taking in some but the predominant portion of the drug is being sloughed off? quid